These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29180684)

  • 21. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance.
    Deshmukh SV; Harsch A
    J Pharmacol Toxicol Methods; 2011; 63(1):35-9. PubMed ID: 20433934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
    Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
    Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.
    Gupta A; Harris JJ; Lin J; Bulgarelli JP; Birmingham BK; Grimm SW
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5986-94. PubMed ID: 27458210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue.
    Kuperman AV; Kalgutkar AS; Marfat A; Chambers RJ; Liston TE
    Drug Metab Dispos; 2001 Nov; 29(11):1403-9. PubMed ID: 11602515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034.
    Sahi J; Sinz MW; Campbell S; Mireles R; Zheng X; Rose KA; Raeissi S; Hashim MF; Ye Y; de Morais SM; Black C; Tugnait M; Keller LH
    Chem Biol Interact; 2006 Feb; 159(2):156-68. PubMed ID: 16356485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition.
    Lundquist P; Englund G; Skogastierna C; Lööf J; Johansson J; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):448-58. PubMed ID: 24396144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract.
    Le Vee M; Jouan E; Stieger B; Lecureur V; Fardel O
    PLoS One; 2015; 10(3):e0121232. PubMed ID: 25803276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of blood protein and target organ DNA and protein binding following topical application of benzo[a]pyrene and 7H-dibenzo[c,g]carbazole to mice.
    Meier JR; Warshawsky D
    Carcinogenesis; 1994 Oct; 15(10):2233-40. PubMed ID: 7955059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions.
    Lundquist P; Lööf J; Sohlenius-Sternbeck AK; Floby E; Johansson J; Bylund J; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):469-80. PubMed ID: 24396146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.
    Vellonen KS; Ihalainen J; Boucau MC; Gosselet F; Picardat T; Gynther M; Kanninen KM; White AR; Malm T; Koistinaho J; Forsberg MM; Ruponen M
    Pharm Res; 2017 Dec; 34(12):2652-2662. PubMed ID: 28952054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
    Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
    J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).
    Liao M; Chuang BC; Zhu Q; Li Y; Guan E; Yu S; Yang J; Prakash S; Xia CQ
    Xenobiotica; 2018 May; 48(5):467-477. PubMed ID: 28485193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake.
    Baker M; Parton T
    Xenobiotica; 2007; 37(10-11):1110-34. PubMed ID: 17968739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
    J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.
    Kalvass JC; Maurer TS; Pollack GM
    Drug Metab Dispos; 2007 Apr; 35(4):660-6. PubMed ID: 17237155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer's disease.
    Van Ess PJ; Pedersen WA; Culmsee C; Mattson MP; Blouin RA
    J Neurochem; 2002 Feb; 80(4):571-8. PubMed ID: 11841564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease.
    Chang KL; Pee HN; Yang S; Ho PC
    Sci Rep; 2015 Mar; 5():9000. PubMed ID: 25760794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the Preclinical Pharmacology of the New 2-Aminomethylphenol, JPC-3210, for Malaria Treatment and Prevention.
    Birrell GW; Heffernan GD; Schiehser GA; Anderson J; Ager AL; Morales P; MacKenzie D; van Breda K; Chavchich M; Jacobus LR; Shanks GD; Jacobus DP; Edstein MD
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29311093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.